Service Introduction

Bioanalytical services

Bioanalysis services: support a wide range of biopharmaceutical modalities, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), nucleic acid drugs/mRNA vaccines, oncolytic viruses (OVs), AAV gene therapy products (GTs), cell therapy products (e.g., CAR-T/iPSCs), fusion proteins, peptides, and small molecule drugs.


Drug Type: Development Stage: Project Services: Analysis Platforms: Management Systems:
Cell and Gene Therapy
Early Development
Method Development
MSD
Watson LIMS
Monoclonal Antibodies
Preclinical
Method Validation
qPCR
Fusion Proteins
Phase I/II/III Clinical
Method Transfer
ELISA
Peptides
Post-Marketing Sample Analysis
FACS
Vaccines
Sample Management Luminex
Small Molecule Drugs LC-MS/MS
AKTA
Our experience

Peptides and protein drugs

Short Peptides:
Exenatide, Teriparatide, Liraglutide

Peptides:
Insulin, EPO, FSH, G-CSF, pegylated G-CSF

Protein Drugs:
GH


Our expertise includes

Monoclonal antibody drugs

Monoclonal Antibodies:
CD20, HER2, VEGF, TNF-α, IL5 , CD38, CGRP, PD1, PD-L1, IL-12/IL-23, LAG-3, RANKL, EGFR, CD73, CD38, GARP, TIGIT, CLDN18.2, CD137, CTLA-4

Bispecific Antibodies:
CD3 x CD20, PD-L1 x TIGIT, EGFR x cMet, EGFR x CD137

ADC:
HER2-ADC, BCMA-ADC


Our expertise includes

Cell and gene therapy

CAR-T:
CD19/BCMA CAR-T

iPSC: 
iPSC-derived platelet

AAV:
AAV2, AAV5, AAV9

oncolytic viruses (OVs)

mRNA

Mini-nucleic acid analogs


Our quality system encompasses

International Platform Standards
Meet the regulatory requirements of China's NMPA, the European Medicines Agency (EMA), and the United States' FDA for biopharmaceutical analysis.
Digital precision management
Adopting electronic systems to manage critical processes and avoid human errors in manual record-keeping, enabling remote auditing by clients and regulatory agencies.
Automated and efficient platform
Large-scale adoption of automated systems for experimental operations, reducing labor costs and improving analytical efficiency.
Independent quality inspection
Equipped with an independent Quality Assurance (QA) department to ensure the authenticity and regulatory compliance of all studies conducted.
Systematic security maintenance
Security maintenance system for analytical and testing data, including dedicated personnel as computer and software system administrators, as well as multiple backups for electronic data management, ensuring the integrity and security of customer data storage.
Process-oriented data recording
To avoid human errors, it is important to establish a Quality Control (QC) program that spans across all stages of the experimental process. This program should include QC checks at every step, including the documentation of raw records, sample borrowing and returning, sample processing, analysis, and data handling. By implementing QC checks at each stage, it helps ensure the accuracy and reliability of the results, minimizing the occurrence of human errors.

Watson LIMS

Our platform and management system include

Convergent Bio Sciences possesses a laboratory that complies with Good Laboratory Practice (GLP) quality standards. We have established immunological analysis platforms, molecular detection analysis platforms, and cellular analysis platforms, among other technical platforms. We provide comprehensive biopharmaceutical analysis services throughout the entire drug development cycle.


Luminex 200

image.png

ABI 7500

QTRAP 6500 / LC-MS/MS


MSD


MD SpectraMax 190


Our advantages include

Capability to provide comprehensive end-to-end services

The core technical team has years of professional experience in biopharmaceutical analysis from leading global biotechnology/pharmaceutical companies.

The core technical team is familiar with various biopharmaceutical analysis methods and R&D processes, well-versed in domestic and international project application and regulatory requirements. With successful experiences in obtaining regulatory approvals for 9 biopharmaceuticals in Europe and the United States and 5 biopharmaceuticals in China, our expertise covers preclinical and clinical phases (Phase I, II, III) of innovative biopharmaceuticals and biosimilars. We have undergone multiple reviews by the FDA, EMA, and CFDI.


Regulatory policies are becoming increasingly stringent, with higher scientific requirements for analytical methods by regulatory agencies.

In recent years, regulatory agencies both domestically and internationally have issued various guidelines and documents related to biopharmaceutical analysis, resulting in more stringent regulatory requirements. Compared to other domestic CROs, our core technical team has unique experience and advantages in developing biopharmaceutical analysis methods. We can effectively address the deficiencies in method development for domestic clients, significantly improving detection efficiency, accelerating the clinical trial process, saving valuable time in drug development, and meeting the declaration requirements of domestic and international regulatory agencies.

The team has extensive experience in managing analytical laboratories, familiar with various technical platforms, and compliant laboratory management systems. It has the capability to provide comprehensive end-to-end services.

With comprehensive technical platforms, we can fully support preclinical and clinical pharmacokinetics, pharmacodynamics, immunogenicity, and biomarker research. We have the complete capability to provide end-to-end services, including the development and validation of biopharmaceutical analysis methods, analysis of preclinical and clinical samples, data analysis, and regulatory submission.

Our well-established laboratory management system ensures automation, electronic record-keeping, and systemization in the major steps of testing and analysis, effectively avoiding human errors and information omissions. Additionally, through the customized design of professional equipment and facilities, we further enhance the efficiency and accuracy of testing and analysis, fully complying with the analytical regulations of China’s NMPA, the European Union’s EMA, and the United States’ FDA.

Please tell us your questions or needs
and Kanwhish Biotech will contact you as soon as possible via email or phone.
Email : BD@Kanwhish.com ADD : 4F, Building C3, No.999 Yinshanhu Road, Wuzhong District, Suzhou, Jiangsu, 215100, China
© 2022 - 2023 CopyrightAll Rights Reserved. ADD:江苏省苏州市吴中区尹山湖路999号C3幢4楼 苏ICP备2023013734号-1
© 2022-2024 Copyright All Rights Reserved. 苏ICP备2023013734号-1